Literature DB >> 20517340

Surgical oncology. Alternatives to surgery after failure of instillation therapy.

Christian Weiss1, Claus Rödel.   

Abstract

Management of high-risk non-muscle-invasive bladder cancer represents a difficult challenge in clinical practice. the dilemma is to decide between an organ-sparing approach or radical cystectomy with the risk of undertreatment or overtreatment for this group of patients. This issue is especially important for patients who have failed previous intravesical therapy.

Entities:  

Mesh:

Year:  2010        PMID: 20517340     DOI: 10.1038/nrclinonc.2010.69

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  10 in total

Review 1.  Bladder cancer: epidemiology, staging and grading, and diagnosis.

Authors:  Ziya Kirkali; Theresa Chan; Murugesan Manoharan; Ferran Algaba; Christer Busch; Liang Cheng; Lambertus Kiemeney; Martin Kriegmair; R Montironi; William M Murphy; Isabell A Sesterhenn; Masaaki Tachibana; Jeff Weider
Journal:  Urology       Date:  2005-12       Impact factor: 2.649

2.  Defining bacillus Calmette-Guerin refractory superficial bladder tumors.

Authors:  Harry W Herr; Guido Dalbagni
Journal:  J Urol       Date:  2003-05       Impact factor: 7.450

3.  Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.

Authors:  Guido Dalbagni; Paul Russo; Bernard Bochner; Leah Ben-Porat; Joel Sheinfeld; Pramod Sogani; Machelle S Donat; Harry W Herr; Dean Bajorin
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

4.  Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?

Authors:  Christian Weiss; Carolin Wolze; Dirk Gerhard Engehausen; Oliver J Ott; Frens S Krause; Karl-Michael Schrott; Jürgen Dunst; Rolf Sauer; Claus Rödel
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

Review 5.  Trimodality treatment and selective organ preservation for bladder cancer.

Authors:  Claus Rödel; Christian Weiss; Rolf Sauer
Journal:  J Clin Oncol       Date:  2006-12-10       Impact factor: 44.544

Review 6.  The global burden of urinary bladder cancer.

Authors:  D Maxwell Parkin
Journal:  Scand J Urol Nephrol Suppl       Date:  2008-09

7.  Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.

Authors:  Raffaele Addeo; Michele Caraglia; Sergio Bellini; Alberto Abbruzzese; Bruno Vincenzi; Liliana Montella; Antonio Miragliuolo; Rosario Guarrasi; Michele Lanna; Gregorio Cennamo; Vincenzo Faiola; Salvatore Del Prete
Journal:  J Clin Oncol       Date:  2009-10-19       Impact factor: 44.544

Review 8.  Treatment options for high-risk T1 bladder cancer: status quo and future perspectives of radiochemotherapy.

Authors:  Christian Weiss; Oliver J Ott; Michael Wittlinger; Steffen F Krause; Rainer Fietkau; Rolf Sauer; Claus Rödel
Journal:  Strahlenther Onkol       Date:  2008-09-19       Impact factor: 3.621

Review 9.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder.

Authors:  Marko Babjuk; Willem Oosterlinck; Richard Sylvester; Eero Kaasinen; Andreas Böhle; Juan Palou-Redorta
Journal:  Eur Urol       Date:  2008-04-30       Impact factor: 20.096

10.  The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?

Authors:  Jennifer Y Wo; William U Shipley; Douglas M Dahl; John J Coen; Niall M Heney; Donald S Kaufman; Anthony L Zietman
Journal:  BJU Int       Date:  2008-12-23       Impact factor: 5.588

  10 in total
  1 in total

Review 1.  Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Aurélien Marabelle; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.